NeuroThera
Phase 3- Indications
- Acute ischemic stroke
Company intelligence / Profile preview
Phothera is a newly formed company resulting from the merger of two leading home phototherapy brands, Daavlin and NatBio. It offers advanced at-home and in-office narrowband UVB phototherapy devices for treating chronic skin conditions such as psoriasis, vitiligo, and eczema. The company's solutions are clinically proven to be safe and effective for a wide range of patients—including children, pregnant women, the elderly, and immunocompromised individuals—with 82% of patients achieving nearly clear skin within five weeks. Devices are FDA-cleared for these indications.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on PhotoThera.